Binding Site Expands mAb Portfolio
Binding Site has introduced a number of new monoclonal antibodies targeting infectious diseases, including cytomegalovirus, hepatitis (A, B, C, and D), herpes, human immunodeficiency virus (HIV), rubella, and toxoplasma.
Binding Site’s Immunologicals Group has expanded its monoclonal antibody (mAb) product offerings. In addition to the established conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, Binding Site has introduced a number of new mAbs targeting infectious diseases, including cytomegalovirus, hepatitis (A, B, C, and D), herpes, human immunodeficiency virus (HIV), rubella, and toxoplasma.
These antibodies are highly specific and demonstrate high levels of purity, extended shelf-life stability, and lot-to-lot consistencies, according to Binding Site. The infectious disease mAbs are all available in a standard-sized 1.0-mg fill format, while the rest come in a standard 0.2-mg fill format. In addition, bulk packaging and customer-specific packaging options are available for all of these mAbs.
Source: Binding Site
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
